Strategic Launch Report and Evaluate Forecast
Predict Payer Uptake of New Drugs With Precision
- Predict Drug Launch Uptake and Market Performance: Forecast one-year uptake of pipeline agents using advanced analytics, real-world data, and market access insights.
- Segment Payers and Channels for Targeted Strategy: Analyze payer and channel segmentation to identify restrictive health plans and PBMs across commercial, Medicare, and other channels.
- Perform Launch Scenario Analysis with Market Analogs: Evaluate comparable drug launches and uptake curves to understand key drivers of success and inform go-to-market strategy.
- Assess Impact of Medical Exceptions and Market Demand: Understand how medical exceptions, payer policies, and market demand influence post-launch sales and overall brand performance.
Turn Market Access Data into Launch-Ready Strategy
What Our Clients Are Saying
"For rare diseases, traditional labs and claims data alone haven’t given us the depth we need to act. Norstella’s EMR data is changing that. The level of clarity is redefining how we go to market."
Director, Commercial and Medical IT, Rare Disease
Global Biotech Company
"For rare diseases, traditional labs and claims data alone haven’t given us the depth we need to act. Norstella’s EMR data is changing that. The level of clarity is redefining how we go to market."
Director, Commercial and Medical IT, Rare Disease
Global Biotech Company
"For rare diseases, traditional labs and claims data alone haven’t given us the depth we need to act. Norstella’s EMR data is changing that. The level of clarity is redefining how we go to market."
Director, Commercial and Medical IT, Rare Disease
Global Biotech Company
"For rare diseases, traditional labs and claims data alone haven’t given us the depth we need to act. Norstella’s EMR data is changing that. The level of clarity is redefining how we go to market."
Director, Commercial and Medical IT, Rare Disease
Global Biotech Company
How We Can Help
Strategic Launch Report and Evaluate Forecast empower commercial teams to generate more accurate drug launch forecasts by leveraging real-world data, payer insights, and competitive intelligence. Even in new indications or highly competitive markets with limited payer coverage, these solutions help teams anticipate uptake, navigate access challenges, and optimize launch strategy.
The Strategic Launch Report helps predict drug uptake and market performance by using real world data, historical analogs, and market access analytics to forecast how a therapy is likely to perform at launch.
The Strategic Launch Report optimizes pre launch payer and market access strategy by analyzing payer behavior, expected coverage restrictions, and segmentation patterns across key payer types.
The Strategic Launch Report reduces launch risk and improves post launch outcomes by leveraging insights from comparable product launches, evolving market trends, and payer policy shifts to guide strategic decision making.
Key Insights From MMIT
Strategies for Early Market Access Planning
This webinar explores how pharmaceutical companies are moving market access planning earlier into phases 1–3 to improve launch readiness, payer alignment, and long-term commercial performance. Speakers discuss how growing competition, pricing pressure, and regulatory changes are increasing the need for early, data-driven access strategy built on analog analysis, payer research, and integrated real-world data. The session also highlights how these insights help manufacturers refine value propositions, shape clinical development decisions, anticipate payer behavior, and strengthen commercialization strategy before launch.
What you’ll learn:
- How historic analogs can help your team decide whether to pursue or license a product.
- When early identification of payer priorities can lead to beneficial adjustments to your product’s value proposition.
- What kind of data helps you anticipate (and circumvent) launch disadvantages.
Solutions to Support Your Strategy
Enhance the Strategic Launch Report with complementary solutions that expand visibility into treatment patterns, coverage trends, and patient access dynamics. By pairing launch forecasting with broader market access intelligence, your team can move from isolated insights to confident, evidence based action.